Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29287648 | 0.78 | CTSK (0.37) | TSHRALDH1A1MMP9HPGDCTSK | |
| SCHEMBL7738388 | 0.77 | CTSK (0.36) | TSHRALDH1A1MMP9CTSK | |
| SCHEMBL2622860 | 0.75 | THRB (0.32) | TSHRMMP9 | |
| SCHEMBL21012236 | 0.73 | — | — | |
| SCHEMBL1170088 | 0.71 | TSHR (0.33) | TSHRALDH1A1MMP9 | |
| SCHEMBL29091396 | 0.70 | CTSK (0.32) | ALDH1A1CTSK | |
| SCHEMBL3185207 | 0.69 | PAM (0.32) | TSHRALDH1A1 | |
| SCHEMBL3184155 | 0.69 | PLA2G2C (0.35) | TSHRALDH1A1CTSK | |
| SCHEMBL8667788 | 0.69 | TSHR (0.49) | TSHRALDH1A1HPGDCTSK | |
| SCHEMBL28540645 | 0.69 | CTSK (0.31) | ALDH1A1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944658-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160024121-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024121-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | TSHR 4759/4885ALDH1A1 305/4885MMP9 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.